Arecor Therapeutics (AREC) Competitors GBX 39.40 +1.40 (+3.68%) As of 04/17/2025 12:29 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesBuy This Stock AREC vs. ETX, SBTX, TRX, COS, C4XD, DDDD, FUM, OKYO, SAR, and AORShould you be buying Arecor Therapeutics stock or one of its competitors? The main competitors of Arecor Therapeutics include e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Tissue Regenix Group (TRX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Futura Medical (FUM), OKYO Pharma (OKYO), Sareum (SAR), and AorTech International (AOR). These companies are all part of the "biotechnology" industry. Arecor Therapeutics vs. e-therapeutics SkinBioTherapeutics Tissue Regenix Group Collagen Solutions plc (COS.L) C4X Discovery 4D pharma Futura Medical OKYO Pharma Sareum AorTech International Arecor Therapeutics (LON:AREC) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Which has better valuation and earnings, AREC or ETX? e-therapeutics has lower revenue, but higher earnings than Arecor Therapeutics. Arecor Therapeutics is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioArecor Therapeutics£6.04M2.46-£10.68M-£28.30-1.39e-therapeutics£295K0.00-£10.06M-£0.02N/A Does the media prefer AREC or ETX? In the previous week, Arecor Therapeutics' average media sentiment score of 0.00 equaled e-therapeutics'average media sentiment score. Company Overall Sentiment Arecor Therapeutics Neutral e-therapeutics Neutral Do insiders & institutionals have more ownership in AREC or ETX? 44.1% of Arecor Therapeutics shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 25.3% of Arecor Therapeutics shares are held by insiders. Comparatively, 59.4% of e-therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the MarketBeat Community believe in AREC or ETX? e-therapeutics received 128 more outperform votes than Arecor Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformArecor TherapeuticsN/AN/Ae-therapeuticsOutperform Votes12860.09% Underperform Votes8539.91% Which has more risk and volatility, AREC or ETX? Arecor Therapeutics has a beta of -0.18, meaning that its stock price is 118% less volatile than the S&P 500. Comparatively, e-therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500. Is AREC or ETX more profitable? e-therapeutics has a net margin of 0.00% compared to Arecor Therapeutics' net margin of -176.89%. e-therapeutics' return on equity of -38.75% beat Arecor Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Arecor Therapeutics-176.89% -118.67% -37.31% e-therapeutics N/A -38.75%-29.10% Summarye-therapeutics beats Arecor Therapeutics on 8 of the 11 factors compared between the two stocks. Get Arecor Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AREC and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AREC vs. The Competition Export to ExcelMetricArecor TherapeuticsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£14.88M£121.01M£5.30B£2.48BDividend YieldN/A3.75%5.12%4.96%P/E Ratio-1.393.0521.86129.75Price / Sales2.464,228.83380.54232,042.22Price / Cash5.0713.1938.2628.07Price / Book2.3834.276.454.43Net Income-£10.68M-£91.73M£3.22B£5.83B7 Day Performance2.34%2.13%2.85%3.01%1 Month Performance-18.34%-5.23%-8.67%-1.06%1 Year Performance-69.34%86.17%11.46%102.51% Arecor Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARECArecor TherapeuticsN/AGBX 39.40+3.7%N/A-69.3%£14.88M£6.04M-1.3910Gap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295,000.00-450.0035High Trading VolumeSBTXSkinBioTherapeuticsN/AGBX 19.25-0.6%N/A+123.6%£43.97M£1.56M-11.8411TRXTissue Regenix GroupN/AGBX 36.06-5.1%N/A-39.1%£32.51M£31.98M-37.23120COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350C4XDC4X DiscoveryN/AN/AN/AN/A£30.27M£24.68M300.0049High Trading VolumeDDDD4D pharmaN/AN/AN/AN/A£30.05M£718,000.00-1.08106FUMFutura MedicalN/AGBX 9.60-2.0%N/A-75.7%£29.92M£8.68M-7.9212Earnings ReportGap DownOKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownSARSareumN/AGBX 17.90+2.3%N/A-17.1%£22.36MN/A-4.243,211Gap DownAORAorTech InternationalN/AN/AN/AN/A£19.99M£539,000.00-33.383 Related Companies and Tools Related Companies e-therapeutics Alternatives SkinBioTherapeutics Alternatives Tissue Regenix Group Alternatives Collagen Solutions plc (COS.L) Alternatives C4X Discovery Alternatives 4D pharma Alternatives Futura Medical Alternatives OKYO Pharma Alternatives Sareum Alternatives AorTech International Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:AREC) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredTrump to unlock 15-figure fortune for America (May 3rd) ?Recently, President Trump decided to kill the coin, for good reason. It now costs 4 cents to make a single pen...Paradigm Press | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arecor Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Arecor Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy AREC Stock Free AREC Stock Alerts